This brand name is authorized in Brazil, Estonia, Lithuania
The drug ALTARGO contains one active pharmaceutical ingredient (API):
1
Retapamulin
UNII 4MG6O8991R - RETAPAMULIN
|
Retapamulin is a semi-synthetic derivative of the compound pleuromutilin, which is isolated through fermentation from Clitopilus passeckerianus. Retapamulin selectively inhibits bacterial protein synthesis by interacting at a unique site on the 50S subunit of the bacterial ribosome that is distinct from the binding sites of other non-pleuromutilin antibacterial agents that interact with the ribosome. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
ALTARGO Ointment | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
D06AX13 | Retapamulin | D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06A Antibiotics for topical use → D06AX Other antibiotics for topical use |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 510611201169211 |
Country: EE | Ravimiamet | Identifier(s): 1299506, 1299517, 1299528, 1299539 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1027224, 1027225, 1027226, 1027227 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.